Waldenstrom's Macroglobulinemia Clinical Trials and Research | Dana‑Farber Cancer Institute

Cancer research · Waldenstrom macroglobulinemia

This practice-changing discovery resulted from our discovery of MYD88 as the most prevalent mutation in WM through whole genome studies.

Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.

Original source

Related signals

• Waldenström Macroglobulinemia Clinical Trials
• European Consortium for Waldenström's Macroglobulinemia
• Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 2- Focus on Therapy
• The therapeutic perspective of relapsed/refractory Waldenström Macroglobulinemia: what comes next?
• Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia